Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 18/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 15/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7975899 | 0.85 | HDAC8 (0.59) | HDAC8HDAC6 | |
| SCHEMBL9453852 | 0.79 | ALDH1A1 (0.54) | CNR2HTR2AHTR2CHTR2B | |
| SCHEMBL216021 | 0.76 | CNR2 (0.54) | CNR2 | |
| SCHEMBL21812506 | 0.76 | CNR2 (0.43) | HDAC6CNR2HTR2B | |
| SCHEMBL9429205 | 0.76 | HDAC8 (0.61) | HDAC8HDAC6HTR2C | |
| SCHEMBL217912 | 0.74 | CNR2 (0.44) | HDAC8HDAC6CNR2 | |
| SCHEMBL16088173 | 0.74 | ALDH1A1 (0.49) | CNR2HTR2AHTR2CHTR2B | |
| SCHEMBL2973928 | 0.73 | ALDH1A1 (0.41) | CNR2HTR2AHTR2CHTR2B | |
| SCHEMBL16199238 | 0.73 | HDAC8 (0.71) | HDAC8HDAC6HDAC2 | |
| SCHEMBL31041845 | 0.72 | ALDH1A1 (0.48) | CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088924-B2 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-8088924-B2 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | SHIONOGI & CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | TADA YUKIO | 2010-04-01 | — | — | US | disclosed |
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | TADA YUKIO | 2010-04-01 | — | — | US | disclosed |
| US-7652141-B2 | Immunosuppressants, analgesics, antiinflammatory agents | SHIONOGI & CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| US-7652141-B2 | Immunosuppressants, analgesics, antiinflammatory agents | SHIONOGI & CO., LTD. (JP) | 2010-01-26 | — | — | US | disclosed |
| EP-2130820-A1 | Antipruritics | SHIONOGI & CO., LTD. (JP) | 2009-12-09 | — | — | EP | disclosed |
| EP-1477186-B1 | ANTIPRURITICS | SHIONOGI & CO (JP) | 2009-11-11 | — | — | EP | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-20080312292-A1 | Antipruritics | YASUI KIYOSHI | 2008-12-18 | — | — | US | disclosed |
| US-20060052411-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | TADA YUKIO | 2006-03-09 | — | — | US | disclosed |
| US-6977266-B2 | Pyridone derivatives having affinity for cannabinoid 2-type receptor | SHIONOGI & CO., LTD. (JP) | 2005-12-20 | — | — | US | disclosed |
| US-20050101590-A1 | Cannabinoid receptor agonists | SHIONOGI & CO., LTD. (JP) | 2005-05-12 | — | — | US | disclosed |
| EP-1477186-A1 | ANTIPRURITICS | SHIONOGI & CO., LTD. (JP) | 2004-11-17 | — | — | EP | disclosed |
| US-20040082619-A1 | Pyridone derivatives having affinity for cannabinoid 2-type receptor | SHIONOGI & CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1357111-A1 | PYRIDONE DERIVATIVE HAVING AFFINITY FOR CANNABINOID 2-TYPE RECEPTOR | SHIONOGI & CO., LTD. (JP) | 2003-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081686-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter | CNR2, CNR1, NPY2R | HDAC8 3683/4885HDAC6 4752/4885HDAC2 2100/4885 |
| US-20050101590-A1 | Cannabinoid receptor agonists | CNR1, CNR2, OPRL1 | HDAC8 1662/4885HDAC6 2465/4885HDAC2 2597/4885 |
| US-20060052411-A1 | Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor | CNR2, CNR1, NPY2R | HDAC8 3330/4885HDAC6 4558/4885HDAC2 1693/4885 |
| US-20080312292-A1 | Antipruritics | CNR1, CNR2, OPRL1 | HDAC8 1056/4885HDAC6 918/4885HDAC2 1142/4885 |
| US-20040082619-A1 | Pyridone derivatives having affinity for cannabinoid 2-type receptor | CNR1, CNR2, NPY1R | HDAC8 3588/4885HDAC6 4666/4885HDAC2 2589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.